Media Library

Presentations From World ADC Asia 2019

Presentation 1

Antibody-drug Conjugates Derived from Cytotoxic Seco-CBI-dimer Payloads are Highly Efficacious in Xenograft Models & Form Protein Adducts in Vivo

By Dian Su, Genentech

Presentation 2

Site-Specific Conjugation & Next-Generation ADCs

By Bruce Han, NewBio Therapeutics

Presentation 3

Development of Series Innovative ADCs Targeting Solid Tumors

By Xiaomai Zhou, DAC Biotech

Check out our speaker interview with Tse-Wen Chang to learn everything from the biggest ADC challenges faced in Asia to first-hand insight on Tse-Wen’s work

Screenshot speaker interview

ADCs: Requirements in terms of GMP and occupational safety

A BCMA-Targeting Antibody-Drug Conjugate with NTERM Conjugation for Treating Multiple Myeloma

Jinwon Jung

Snip Jinwon

ADCs with high ADR, high targeting valence, and product homogeneity

Tse Wen Chang, Ph.D. CEO, Immunwork, Inc.

Snip ADCs with high ADR

Development of Innovative ADCs Targeting Solid Tumors

Xiaomai Zhou

SNIP Development of Innovative ADCs

World ADC Asia Infographic

Infographic screenshot

Clinical Development of ADC-IO Combinations: Today and Tomorrow

Jay Harper, Ph.D., MedImmune Oncology Research

Screenshot clinical dev

Antibody Drug Conjugates: Process Development and Analytical Considerations

Michael Hay – Bristol-Myers Squibb

Streenshot antibody drug

Immunogenicity Assay Strategies for Antibody-Drug Conjugates

Seema Kumar, PhD, EMD Serono Research & Development Institute

Screenshot immunogen

Controlling Contamination and Cross-Contamination